 Connection
Robert MacLaren to Recombinant Proteins
This is a "connection" page, showing publications Robert MacLaren has written about Recombinant Proteins.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.872 |
|
|
|
-
MacLaren R, Weber LA, Brake H, Gardner MA, Tanzi M. A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes. Transfusion. 2005 Sep; 45(9):1434-42.
Score: 0.182
-
Buckley MS, Benanti GE, Meckel J, Tekle LA, Gilbert B, Puebla Neira D, McNierney DA, Korkames G, Yerondopoulos M, Park A, O'Hea JA, MacLaren R. Correlation between partial thromboplastin time and thromboelastography in adult critically ill patients requiring bivalirudin for extracorporeal membrane oxygenation. Pharmacotherapy. 2023 03; 43(3):196-204.
Score: 0.153
-
Stevens VM, Trujillo TC, Kiser TH, MacLaren R, Reynolds PM, Mueller SW. Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding. Clin Appl Thromb Hemost. 2021 Jan-Dec; 27:10760296211039020.
Score: 0.132
-
Kwon JO, MacLaren R. Comparison of Fresh-Frozen Plasma, Four-Factor Prothrombin Complex Concentrates, and Recombinant Factor VIIa to Facilitate Procedures in Critically Ill Patients with Coagulopathy from Liver Disease: A Retrospective Cohort Study. Pharmacotherapy. 2016 10; 36(10):1047-1054.
Score: 0.098
-
Owen PS, Tan EC, Kiser TH, Fish DN, MacLaren R. Reliability and accuracy of practitioner-calculated Acute Physiology and Chronic Health Evaluation II scores for determining the appropriateness of drotrecogin alfa (activated). Am J Health Syst Pharm. 2010 Jan 15; 67(2):136-43.
Score: 0.062
-
MacLaren R. Key concepts in the management of difficult hemorrhagic cases. Pharmacotherapy. 2007 Sep; 27(9 Pt 2):93S-102S.
Score: 0.052
-
Maclaren R. Factor VIIa: mounting evidence or anecdotal reports. J Postgrad Med. 2007 Jan-Mar; 53(1):4-5.
Score: 0.050
-
MacLaren R, Sullivan PW. Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients. Value Health. 2005 Mar-Apr; 8(2):105-16.
Score: 0.044
-
MacLaren R, Gasper J, Jung R, Vandivier RW. Use of exogenous erythropoietin in critically ill patients. J Clin Pharm Ther. 2004 Jun; 29(3):195-208.
Score: 0.042
-
Kiser TH, MacLaren R, Fish DN, Hassell KL, Teitelbaum I. Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy. Pharmacotherapy. 2010 Nov; 30(11):1117-26.
Score: 0.016
-
Mueller SW, MacLaren R, Fish DN, Kiser TH. Prefilter bivalirudin for preventing hemofilter occlusion in continuous renal replacement therapy. Ann Pharmacother. 2009 Jul; 43(7):1360-5.
Score: 0.015
-
Owen PS, Golightly LK, MacLaren R, Ferretti KA, Badesch DB. Formulary management of recombinant factor VIIa at an academic medical center. Ann Pharmacother. 2008 Jun; 42(6):771-6.
Score: 0.014
-
Kiser TH, Jung R, MacLaren R, Fish DN. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia. Pharmacotherapy. 2005 Dec; 25(12):1736-45.
Score: 0.012
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|